Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer

Karol PolomUnit of General and Minimally Invasive Surgery, Surgery and Neuroscience, University of Sienna, Sienna;

Giandomenico RovielloSection of Pharmacology and University Centre, DIFF – Drug Innovation Forward Future, Department of Molecular and Translational Medicine, University of Brescia, Brescia; ;Unit of Molecular Therapy and Pharmacogenomics, AO Azienda Istituti Ospitalieri di Cremona, Cremona; Correspondence[email protected]

Daniele GeneraliUnit of Molecular Therapy and Pharmacogenomics, AO Azienda Istituti Ospitalieri di Cremona, Cremona; ;Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste;

Luigi MaranoGeneral, Minimally Invasive, and Robotic Surgery, Department of Surgery, ‘San Matteo degli Infermi’ Hospital, Spoleto;

Roberto PetrioliMedical Oncology Unit, University of Sienna, Sienna;

Stefania MarsiliMedical Oncology Unit, University of Sienna, Sienna;

Edda CaputoUnit of General and Minimally Invasive Surgery, Surgery and Neuroscience, University of Sienna, Sienna;

Daniele MarrelliDepartment of Medical, Surgical and Neurosciences, Section of Advanced Surgical Oncology, University of Sienna, Sienna, Italy

Franco RovielloUnit of General and Minimally Invasive Surgery, Surgery and Neuroscience, University of Sienna, Sienna;

show all

Abstract

Hyperthermic intraperitoneal chemotherapy (HIPEC), a strategy combining maximal cytoreductive surgery and maximal regional chemotherapy, has been applied to treat ovarian cancer resulting in long-term survival rates in selected patients. However, the status of HIPEC in ovarian cancer remains an experimental procedure, given the many variables among the data and trials reviewed, to enable us to derive strong conclusions about its role from this overview. In this review we discuss treatment with HIPEC in patients with ovarian cancer and future prospective of its use in clinical setting. HIPEC is an effective tool in the treatment of selected patients with peritoneal carcinomatosis from ovarian cancer. Unfortunately, due to the lack of randomised trials, the evidence of HIPEC is very limited. Future randomised studies are awaited to define the role and clinical impact of HIPEC in ovarian cancer.

Keywords:

Acknowledgements

All authors contributed equally to this work.

Disclosure statement

The Authors have no conflict of interest or financial ties to disclose. The authors alone are responsible for the content and writing of the paper.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer

Information for

Open access

Opportunities

Help and information

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer

Abstract

Acknowledgements

Disclosure statement

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature